Key Highlights
- Humacyte (NASDAQ:HUMA) closed at USD 0.5830 on Tuesday, November 10, 2026, up 28.08% from a calculated prior close of USD 0.4552, a gain of USD 0.1278 per share, among the session's top gainers.
- Volume reached 6.98 million shares at a relative Volume of 1.62, implying a recent average near 4.31 million shares and about USD 4.07 million traded at the closing price (both calculated).
- The company scheduled its third-quarter and nine-month 2026 results, a Business update and an 8:00 a.m. ET webcast for November 10, 2026, according to its November 2, 2026 notice.
- Market value is USD 161.96 million, trailing diluted EPS is USD -0.49 with EPS growth of -7.27%, there is no P/E, and the Dividend Yield is 0.00%.
What Moved Humacyte on November 10 (+28.08%)
The regular session of Tuesday, November 10, 2026 ended with the shares at USD 0.5830, against a calculated USD 0.4552 on Monday, November 9. That is a rise of 28.08%. The company had named November 10 for its third-quarter 2026 release and webcast. On November 9 it also highlighted a first-in-human coronary bypass study at the AHA Scientific Sessions 2026, after a November 3 notice on the same meeting. Earlier items include an October 28 Patent covering Symvess and other bioengineered tissues with protection into 2043, an October 23 Phase 3 result in women at ASN Kidney Week showing an advantage for the ATEV over a fistula, and an October 15 update that hospitals ordering Symvess rose 44%, from 34 to 49, as of September 30. The figures inside the November 10 release were not available for this review.
The Rationale: Results Day and Commercial Momentum
The identified catalyst is the scheduled third-quarter report together with a run of clinical and commercial updates, but published coverage did not show which single item drove the buying. On September 9, 2026 the company said the FDA authorized extending Symvess shelf life from 18 to 36 months, which can reduce product wastage at hospitals. As general context, a stock priced below USD 1.00 often moves sharply on results days because small changes in Revenue or cash runway shift expectations for dilution. A rise of 15 hospitals in one quarter shows adoption, yet a base of 49 hospitals does not show profitability, and the trailing loss of USD 0.49 per share equals about 84% of the share price (calculated).
Valuation, Liquidity and Risks
With a Market Value of USD 161.96 million, the implied share count is about 277.8 million (calculated), so any new Equity issuance would dilute holders materially. A published snapshot cited liquidity near USD 80 million and burn near USD 7 million a month, roughly eight months of runway, but this was not confirmed against a filing and should be treated as unverified. Trailing EPS growth of -7.27% shows the loss widened. As general context, a share price under USD 1.00 can draw Nasdaq minimum bid scrutiny if it persists. Relative volume of 1.62 means activity was above average, yet a small number of trades can move a price this low, and spreads can be wide. Nothing here implies the move will continue.
Where Things Stand
Humacyte (NASDAQ:HUMA) rose 28.08% to USD 0.5830 on November 10, 2026, a session that coincided with its scheduled third-quarter results and webcast at 8:00 a.m. ET, after a month of clinical and commercial news. The calculated prior close was USD 0.4552. With 6.98 million shares traded and a market value of USD 161.96 million, the stock remains a high-risk, dilution-sensitive name.






Please wait processing your request...